Effect of transcutaneous auricular vagus nerve stimulation on enteral nutrition feeding in ICU patients

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400085474

Enrollment

Unknown

Registered

2024-06-07

Start date

2024-06-17

Completion date

Unknown

Last updated

2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

critical ill patients

Interventions

Sham TAVNS(Transcutaneous Auricular Vagus Nerve Stimulation)group:Wear an transtaneous auricular vagus nerve stimulator, but do not give electrical stimulation

TAVNS(Transcutaneous Auricular Vagus Nerve Stimulation)group:Transcutaneous Auricular vagus nerve stimulation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Expected to stay in ICU for more than one week; 2. Age >= 18 years old, gender unlimited; 3. Have enteral nutritional indications and nutritional risk screening scores of 3-7; 4. Patients voluntarily or their families agree to participate in the trial and sign the informed consent letter.

Exclusion criteria

Exclusion criteria: 1. The primary disease is gastrointestinal disease, such as gastrointestinal ulcer, atrophic gastritis, gastric cancer, etc. 2.Patients after gastrointestinal surgery; 3. Patients with malignant tumors, end-stage patients, extremely severe craniocerebral injury, poor prognosis or possible death in the short term; 4. Local skin infection can not be placed electrode; 5. Patients with permanent cardiac pacemaker installation; 6. Pregnant and lactating women; 7. Unable to maintain a resting state (such as epilepsy, Parkinson's disease); 8. Patients or their family members do not agree to sign the test informed consent.

Design outcomes

Primary

Measure	Time frame
the proportion of subjects receiving > 80% estimated enteral nutrition energy target;	—

Secondary

Measure	Time frame
AGI grading evaluation;Incidence of feeding intolerance within 7 days, incidence of new infections;Gastric residual volume and intra-abdominal pressure;SOFA score and APACHE II score;Complications and treatments;Incidence of aspiration within 7 days;Gut miacrobiota composition;ICU stay;28 day mortality;Enteral nutrition accounted for the proportion of total energy of enteral and parenteral nutrition;	—

Measure

Time frame

AGI grading evaluation;Incidence of feeding intolerance within 7 days, incidence of new infections;Gastric residual volume and intra-abdominal pressure;SOFA score and APACHE II score;Complications and treatments;Incidence of aspiration within 7 days;Gut miacrobiota composition;ICU stay;28 day mortality;Enteral nutrition accounted for the proportion of total energy of enteral and parenteral nutrition;

—

Countries

China

Contacts

Public ContactWu Zhiyang

Qilu Hospital of Shandong University (Qingdao)

wzy838983646@126.com+86 185 6181 2387

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026